- Home
- MRNA vs BMRN Comparison
MRNA vs BMRN Comparison
Compare MRNA & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRNA | BMRN |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3B | 10.5B |
| IPO Year | 2018 | 1999 |
Fundamental Metrics
Financial Performance| Metric | MRNA | BMRN |
|---|---|---|
| Price | $27.57 | $53.19 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 19 |
| Target Price | $33.91 | ★ $88.42 |
| AVG Volume (30 Days) | ★ 9.9M | 3.0M |
| Earning Date | 11-06-2025 | 10-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.53 |
| EPS | N/A | ★ 2.68 |
| Revenue | $2,232,000,000.00 | ★ $3,094,001,000.00 |
| Revenue This Year | N/A | $13.39 |
| Revenue Next Year | $0.77 | $7.57 |
| P/E Ratio | ★ N/A | $19.92 |
| Revenue Growth | N/A | ★ 12.39 |
| 52 Week Low | $22.28 | $50.76 |
| 52 Week High | $48.92 | $73.51 |
Technical Indicators
Market Signals| Indicator | MRNA | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 60.85 | 46.19 |
| Support Level | $23.92 | $53.03 |
| Resistance Level | $26.00 | $54.66 |
| Average True Range (ATR) | 1.29 | 1.45 |
| MACD | 0.32 | -0.11 |
| Stochastic Oscillator | 99.82 | 31.61 |
Price Performance
Historical ComparisonAbout MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.